心力衰竭与新发癌症无关联
该研究基于医师健康研究I和II的28,341名男性医师队列,中位随访19.9年,发现1,420例心衰和7,363例癌症。多变量调整后,心衰与新发癌症风险无关(HR 1.05,95%CI 0.86-1.29),与部位特异性癌症发病率及癌症特异性死亡率也无关联,地标法分析结果一致。
要点
- 在男性医师队列中,心衰未增加总体癌症发病风险(调整后HR 1.05)。
- 心衰与部位特异性癌症发病率及癌症特异性死亡率均无显著关联。
- 不同地标年龄(65、75、80岁)分析结果与主分析一致。
核心结论
- 在男性医师中,心力衰竭与新发癌症风险、部位特异性癌症发病率及癌症特异性死亡率均无关联。
研究设计与样本
- 研究队列来自医师健康研究I和II两项随机对照试验,共纳入28,341名参与者,中位随访19.9年(四分位距11.0-26.8年)。
- 主分析排除基线时已有癌症或心衰者,采用多变量调整Cox模型,将心衰作为时变暴露。
- 补充分析采用地标法,在70岁时识别无癌症参与者并区分有无心衰,另在65、75、80岁进行敏感性分析。
主要发现
- 随访期间1,420例发生心衰,7,363例发生癌症。
- 心衰与癌症发病风险在粗分析中HR 0.92(95%CI 0.80-1.08),多变量调整后HR 1.05(95%CI 0.86-1.29)。
- 多变量调整后,心衰与部位特异性癌症发病率及癌症特异性死亡率均无关联。
- 采用地标法在65、75、80岁分析,结果与主分析相似。
临床怎么用
- 对于男性心衰患者,无需因心衰本身而额外增加癌症筛查强度,仍按常规指南进行年龄和性别适用的癌症筛查。
局限性
- 研究人群仅限男性医师,结果外推至女性或一般人群需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several recent studies have suggested an increased cancer risk among patients with heart failure (HF). However, these studies are constrained by limited size and follow-up, lack of comprehensive data on other health attributes, and adjudicated cancer outcomes. OBJECTIVES: This study sought to determine whether HF is associated with cancer incidence and cancer-specific mortality. METHODS: The study assembled a cohort from the Physicians' Health Studies I and II, 2 randomized controlled trials of aspirin and vitamin supplements conducted from 1982 to 1995 and from 1997 to 2011, respectively, that included annual health evaluations and determination of cancer and HF diagnoses. In the primary analysis, the study excluded participants with cancer or HF at baseline and performed multivariable-adjusted Cox models to determine the relationship between HF and cancer, modeling HF as a time-varying exposure. In a complementary analysis, the study used the landmark method and identified cancer-free participants at 70 years of age, distinguishing between those with and without HF, and likewise performed Cox regression. Sensitivity analyses were performed at 65, 75, and 80 years of age. RESULTS: Among 28,341 Physicians' Health Study participants, 1,420 developed HF. A total of 7,363 cancers developed during a median follow-up time of 19.9 years (25th to 75th percentile: 11.0 to 26.8 years). HF was not associated with cancer incidence in crude (hazard ratio: 0.92; 95% confidence interval: 0.80 to 1.08) or multivariable-adjusted analysis (hazard ratio: 1.05; 95% confidence interval: 0.86 to 1.29). No association was found between HF and site-specific cancer incidence or cancer-specific mortality after multivariable adjustment. Results were similar when using the landmark method at all landmark ages. CONCLUSIONS: HF is not associated with an increased risk of cancer among male physicians.
引用
- Selvaraj S, Bhatt DL, Claggett B, et al. Lack of Association Between Heart Failure and Incident Cancer. J Am Coll Cardiol. 2018. PMID: 29622155. doi:10.1016/j.jacc.2018.01.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。